These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 12242516)

  • 41. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
    Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Potential role of dendritic cell vaccination with MAGE peptides in gastrointestinal carcinomas.
    Tanaka F; Haraguchi N; Isikawa K; Inoue H; Mori M
    Oncol Rep; 2008 Nov; 20(5):1111-6. PubMed ID: 18949409
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
    Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
    Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Inhibitory effect of dendritic cells pulsed with MAGE-3 peptide on transplanted murine gastric cancer in mice].
    Lü B; Liu BY; Zhang Y; Chen XH; Zhu ZG; Yin HR; Lin YZ
    Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2120-3. PubMed ID: 16313822
    [TBL] [Abstract][Full Text] [Related]  

  • 46. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL.
    Dubsky P; Saito H; Leogier M; Dantin C; Connolly JE; Banchereau J; Palucka AK
    Eur J Immunol; 2007 Jun; 37(6):1678-90. PubMed ID: 17492620
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of various sources of antigen-presenting cells for the generation of GP2-tumor peptide specific cytotoxic T-lymphocytes.
    Peiper M; Goedegebuure PS; Alldinger I; Knoefel WT; Izbicki JR; Eberlein TJ
    Anticancer Res; 2002; 22(6A):3357-63. PubMed ID: 12530087
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide.
    Oh ST; Kim CH; Park MY; Won EH; Sohn HJ; Cho HI; Kang WK; Hong YK; Kim TG
    Vaccine; 2006 Apr; 24(15):2860-8. PubMed ID: 16443309
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [In vitro induction of immune response by dendritic cells pulsed with TRAG-3-derived cytotoxic T lymphocyte epitope].
    Zhu B; Chen ZT; Cheng XM; Wu YZ
    Zhonghua Zhong Liu Za Zhi; 2004 Dec; 26(12):709-12. PubMed ID: 15733385
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
    Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
    Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53.
    Umano Y; Tsunoda T; Tanaka H; Matsuda K; Yamaue H; Tanimura H
    Br J Cancer; 2001 Apr; 84(8):1052-7. PubMed ID: 11308253
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.
    Eura M; Chikamatsu K; Katsura F; Obata A; Sobao Y; Takiguchi M; Song Y; Appella E; Whiteside TL; DeLeo AB
    Clin Cancer Res; 2000 Mar; 6(3):979-86. PubMed ID: 10741724
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
    Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.
    Okano F; Storkus WJ; Chambers WH; Pollack IF; Okada H
    Clin Cancer Res; 2002 Sep; 8(9):2851-5. PubMed ID: 12231526
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy.
    Onaitis MW; Kalady MF; Emani S; Abdel-Wahab Z; Tyler DS; Pruitt SK
    Surgery; 2003 Aug; 134(2):300-5. PubMed ID: 12947333
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells.
    Kawashima I; Tsai V; Southwood S; Takesako K; Sette A; Celis E
    Cancer Res; 1999 Jan; 59(2):431-5. PubMed ID: 9927058
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements.
    Huarte E; Sarobe P; Lu J; Casares N; Lasarte JJ; Dotor J; Ruiz M; Prieto J; Celis E; Borrás-Cuesta F
    Clin Cancer Res; 2002 Jul; 8(7):2336-44. PubMed ID: 12114438
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recognition of gp43 tumor-associated antigen peptide by both HLA-A2 restricted CTL lines and antibodies from melanoma patients.
    Takahashi T; Irie RF; Morton DL; Hoon DS
    Cell Immunol; 1997 Jun; 178(2):162-71. PubMed ID: 9225007
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells.
    Stronen E; Abrahamsen IW; Gaudernack G; Wälchli S; Munthe E; Buus S; Johansen FE; Lund-Johansen F; Olweus J
    Scand J Immunol; 2009 Apr; 69(4):319-28. PubMed ID: 19284496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.